Kymera Therapeutics Inc.

28.00
-1.62 (-5.47%)
At close: Mar 31, 2025, 9:54 AM
-5.47%
Bid 27.88
Market Cap 1.82B
Revenue (ttm) 38.22M
Net Income (ttm) -181.76M
EPS (ttm) -2.98
PE Ratio (ttm) -9.39
Forward PE -12.6
Analyst Buy
Ask 28.15
Volume 35,694
Avg. Volume (20D) 578,400
Open 28.75
Previous Close 29.62
Day's Range 26.99 - 28.75
52-Week Range 26.99 - 53.27
Beta 2.23

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 21, 2020
Employees 188
Stock Exchange NASDAQ
Ticker Symbol KYMR
Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $57, which is an increase of 103.61% from the latest price.

Stock Forecasts

Next Earnings Release

Kymera Therapeutics Inc. is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+7.61%
Kymera Therapeutics shares are trading higher. Ste... Unlock content with Pro Subscription
2 months ago
+7.79%
Kymera Therapeutics shares are trading higher after the company announced it's targeting 2025 milestones with its STAT6 and TYK2 oral degraded programs for immunology.